Sanofi · Healthcare · Drug Manufacturers - General
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$48.47
+$0.75 (+1.57%) 12:59 PM ET
Prev closePrevC$47.72
OpenOpen$48.51
Day highHigh$48.58
Day lowLow$48.17
VolumeVol999,269
Avg volAvgVol3,354,662
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$114.33B
Sector
Healthcare
AI report sections
MIXED
SNY
Sanofi
Sanofi’s ADR trades modestly above short-term moving averages with a mid-range RSI, indicating balanced but slightly constructive near-term momentum. Medium-horizon returns over 3–6 months are mildly negative and the price sits in the lower half of its 52-week range, pointing to subdued intermediate performance. A sizeable equity base, moderate leverage, and low short-interest levels provide fundamental and positioning support, while elevated short-volume ratios and concentration in a single blockbuster drug highlight ongoing risk factors.
China Diabetes Devices Market Forecast and Company Analysis Report 2026-2034 Featuring Roche, Abbott Laboratories, Novo Nordisk, BD, Medtronic, Eli Lilly, and Sanofi
China's diabetes devices market is projected to grow from USD 7.19 billion in 2025 to USD 14.51 billion by 2034, with a CAGR of 8.11%. Growth is driven by rising diabetes prevalence (118 million patients), aging population, government healthcare reforms, and technological advancements in glucose monitoring and insulin delivery systems. Key challenges include cost sensitivity and uneven reimbursement coverage across regions.
Identified as a key player in the China diabetes devices market, benefiting from rising diabetes prevalence and government healthcare reforms expanding device accessibility.
PositiveGlobeNewswire Inc.• Delveinsight
Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight
The US eosinophilic esophagitis market is projected to grow at 13.2% CAGR through 2036, driven by increased disease awareness, standardized diagnostics, and high relapse rates. The market was valued at $647 million in 2025, with emerging therapies from major pharmaceutical companies expected to transform the treatment landscape, including TSLP inhibitors, glucocorticoid receptor agonists, and immunomodulators.
Co-markets Dupilumab (DUPIXENT), the first and only approved biologic for EoE (US 2022, Europe approved). Established market presence positions Sanofi to benefit from the expanding patient population and market growth.
PositiveGlobeNewswire Inc.• Sanofi/Regeneron
Communiqué de presse : Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants
La Commission européenne a approuvé Dupixent (dupilumab) pour traiter l'urticaire chronique spontanée modérée à sévère chez les enfants âgés de 2 à 11 ans. Cette approbation élargit l'utilisation du médicament, qui inhibe la signalisation de l'IL-4 et de l'IL-13, et en fait le premier traitement ciblé pour cette indication pédiatrique en Europe. Les données cliniques montrent une réduction significative de l'activité de l'urticaire par rapport au placebo.
SNYREGNDupixentdupilumaburticaire chronique spontanéeapprobation UEenfantsinflammation de type 2
Sentiment note
Approbation réglementaire majeure pour Dupixent dans une nouvelle indication pédiatrique, élargissant le marché potentiel du médicament phare. Cela représente une avancée thérapeutique significative et renforce la position de Sanofi dans le portefeuille des maladies inflammatoires de type 2.
PositiveGlobeNewswire Inc.• Sanofi And Regeneron
Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
The European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria in children aged 2-11 years, expanding its previous approval for adults and adolescents. The approval is based on the LIBERTY-CUPID clinical study program, demonstrating significant reduction in urticaria activity compared to placebo. This marks Dupixent's fourth approval for young children with type 2 inflammation-driven diseases.
Regulatory approval of Dupixent for a new pediatric indication expands the drug's market potential and demonstrates successful clinical development. This approval extends treatment options to a younger patient population and strengthens Sanofi's position in the immunology market.
Atopic Dermatitis (7MM) Drug Market Forecast and Analysis Report 2023-2033: Opportunities Remain for the Treatment of AD, Novel Systemic Therapies Dominate the Late-stage Pipeline
The atopic dermatitis market across seven major markets (US, France, Germany, Italy, Spain, UK, Japan) is projected to grow from $8.5 billion in 2023 to $21.5 billion by 2033, with a CAGR of 9.8%. Growth will be driven by seven late-stage pipeline drugs, expanded treatment options across all age groups and severities, and novel mechanisms of action including JAK inhibitors and IL-inhibiting biologics.
Atopic Dermatitis 68-Market Drug Forecast and Market Analysis Report 2023-2025 & 2025-2033
The global atopic dermatitis market is expected to grow from $10.8 billion in 2023 to $26.2 billion by 2033, driven by seven late-stage pipeline agents, expanded treatment options across demographics, and high treatment rates in key markets. The market will grow at a CAGR of 9.3% over the forecast period.
Featured as a major player in the growing atopic dermatitis market with strong market presence
NeutralGlobeNewswire Inc.• Researchandmarkets.Com
Crohn's Disease Eight-Market Drug Forecast and Market Analysis Report 2025-2026: Novel MOAs Will Provide Market Shifts Throughout the Forecast Period to 2032
The Crohn's Disease therapeutics market across eight major markets is projected to grow from $9.5 billion to $13.8 billion by 2032 at a CAGR of 3.9%, driven by approvals of 8 pipeline, generic, and biosimilar therapies. Novel mechanisms of action and emerging treatments will reshape the competitive landscape, with key opportunities in strategic licensing and partnerships.
Included in company list but no specific information provided about their Crohn's Disease pipeline or competitive positioning.
NeutralGlobeNewswire Inc.• Na
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Nurix Therapeutics reported Q1 2026 financial results with revenue of $6.3 million (down from $18.5 million YoY) and net loss of $87.2 million. The company is advancing its registrational program for bexobrutideg with Phase 2 DAYBreak CLL-201 enrollment ongoing for accelerated approval in relapsed/refractory CLL, and plans to initiate Phase 3 DAYBreak CLL-306 by mid-2026. Nurix maintains a strong cash position of $540.7 million and is expanding bexobrutideg into immunology/inflammation indications with a new tablet formulation targeting 2026 IND submission.
Sanofi is advancing STAT6 degrader (NX-3911) in IND-enabling studies with Nurix retaining opt-in rights to 50/50 U.S. profit share. Early-stage development with uncertain timeline to clinical proof of concept. Represents exploratory collaboration with limited near-term financial impact.
NeutralBenzinga• Vandana Singh
Biogen Taps Alloy Platform To Push Antisense Drug Pipeline Forward
Biogen has entered into an agreement with Alloy Therapeutics to accelerate the development of antisense therapies for multiple undisclosed indications. Alloy's AntiClastic ASO platform aims to improve the effectiveness of antisense therapeutics by targeting disease pathways at the RNA level. This partnership follows Alloy's January 2025 collaboration with Sanofi and Biogen's recent acquisition of Apellis Pharmaceuticals for $5.6 billion.
BIIBAPLSSNYantisense therapiesRNA-targeted drug developmentAntiClastic ASO platformdrug pipeline expansionpartnership agreement
Sentiment note
Sanofi's collaboration with Alloy is mentioned as context but no new developments are reported; the partnership was established in January 2025.
PositiveBenzinga• Vandana Singh
From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker
Sanofi reported positive Phase 2 data for lunsekimig, its bispecific antibody targeting TSLP and IL-13. The drug met primary endpoints in asthma and nasal polyp studies with significant improvements in exacerbations and polyp size. However, an atopic dermatitis trial missed its primary endpoint, though secondary measures showed some clinical activity. The drug demonstrated a favorable safety profile across all studies.
Lunsekimig met primary endpoints in two key indications (asthma and nasal polyps) with statistically significant improvements. Strong safety profile and ongoing Phase 3 trials support positive momentum, though the atopic dermatitis trial miss provides some caution.
PositiveGlobeNewswire Inc.• Sanofi
Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP
Sanofi announced that lunsekimig, a bispecific antibody targeting TSLP and IL-13, met primary and key secondary endpoints in phase 2 studies for moderate-to-severe asthma (AIRCULES) and chronic rhinosinusitis with nasal polyps (DUET). The drug demonstrated statistically significant reductions in exacerbations and improvements in lung function. However, the exploratory VELVET study in atopic dermatitis did not meet its primary endpoint, though secondary endpoints showed improvements. Lunsekimig was well tolerated across all studies.
SNYlunsekimigphase 2 clinical trialsasthmachronic rhinosinusitis with nasal polypsatopic dermatitisTSLPIL-13
Sentiment note
Lunsekimig successfully met primary and key secondary endpoints in two important respiratory disease indications (asthma and CRSwNP), demonstrating clinical efficacy and good tolerability. This represents meaningful progress in the drug development pipeline with potential for significant market opportunity. While the atopic dermatitis study did not meet its primary endpoint, secondary endpoints showed promise. The positive respiratory data outweighs the dermatitis setback.
PositiveGlobeNewswire Inc.• Sanofi
Communiqué de presse: Le lunsekimig de Sanofi a atteint les critères d’évaluation principal et secondaires clés dans les études respiratoires de phase 2 dans l’asthme et la rhinosinusite chronique avec polypose nasale
Sanofi announced that lunsekimig, a novel bispesific Nanobody, met primary and key secondary endpoints in Phase 2b AIRCULES study for moderate-to-severe asthma and Phase 2a DUET study for chronic rhinosinusitis with nasal polyps. The drug demonstrated statistically significant reductions in exacerbations and improved lung function. However, the exploratory Phase 2b VELVET study in atopic dermatitis failed to meet its primary endpoint. Lunsekimig was generally well-tolerated across all studies.
Sanofi achieved positive clinical trial results in two respiratory indications (asthma and chronic rhinosinusitis with nasal polyps), demonstrating efficacy and safety of lunsekimig. These successes support advancement to Phase 3 trials and expand the company's pipeline in high-need therapeutic areas. However, the failure in atopic dermatitis slightly tempers the overall positive outlook.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal